NEW YORK, March 1, 2018 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community.Today we are offering reports on RIGL, MDCO, VSAR, and ZTS which can be accessed for free by signing up to www.wallstequities.com/registration. WallStEquities.com has issued research reports on Rigel Pharmaceuticals Inc. (NASDAQ: RIGL), The Medicines
On Wednesday, shares in South San Francisco, California-based Rigel Pharmaceuticals Inc. recorded a trading volume of 1.23 million shares. The stock ended at $3.76, declining slightly by 0.79% from the last trading session. The Company's shares have gained 53.47% over the past year. The stock is trading above its 200-day moving average by 17.73%. Furthermore, shares of Rigel Pharma, which engages in the discovery and development of drugs in the therapeutic areas of immunology, oncology, and immuno-oncology, have a Relative Strength Index (RSI) of 45.19.
On February 27th, 2018, Rigel Pharma announced that it will report its Q4 and year-end 2017 financial results after market close on March 06th, 2018. Senior management will host a live conference call at 5:00 p.m. ET that same day to discuss the results and provide a Company update. The conference call will be webcast live and can be accessed on the Company's website. Get the full research report on RIGL for free by clicking below at: www.wallstequities.com/registration/?symbol=RIGL
Parsippany, New Jersey-based The Medicines Co.'s stock finished yesterday's session 2.11% lower at $30.62 with a total trading volume of 831,677 shares. The Company's shares have gained 0.10% over the previous three months. The stock is trading above its 50-day moving average by 3.85%. Furthermore, shares of Medicines Co., which provides medicines for patients in acute and intensive care hospitals worldwide, have an RSI of 47.91.
On February 27th, 2018, Medicines Co. announced that its Board of Directors has appointed Dr. Sarah Schlesinger as a new, independent Director of the Company, effective immediately. Dr. Schlesinger has spent more than 20 years working in the field of cellular immunity. She is currently the Chair of The Rockefeller University Hospital's Institutional Review Board, and the Senior Physician and Associate Professor of Clinical Investigation at The Rockefeller University. The free technical report on MDCO can be accessed at: www.wallstequities.com/registration/?symbol=MDCO
At the close of trading on Wednesday, shares in Menlo Park, California headquartered Versartis Inc. ended the day flat at $1.60. The stock recorded a trading volume of 772,945 shares. The Company's shares are trading 18.95% below their 50-day moving average. Moreover, shares of Versartis, which operates as an endocrine-focused biopharmaceutical company in the US, have an RSI of 26.31. Sign up for free on Wall St. Equities and claim the latest report on VSAR at: www.wallstequities.com/registration/?symbol=VSAR
Parsippany, New Jersey headquartered Zoetis Inc.'s shares ended the day 0.99% lower at $80.86 with a total trading volume of 1.97 million shares. The stock has gained 2.12% in the last month, 13.03% over the previous three months, and 51.68% over the past year. The Company's shares are trading 7.00% above their 50-day moving average and 20.43% above their 200-day moving average. Additionally, shares of Zoetis, which discovers, develops, manufactures, and markets veterinary vaccines and medicines in the US and internationally, have an RSI 61.46.
On February 13th, 2018, Zoetis' Board of Directors has declared a Q2 2018 dividend, payable to holders of the Company's common stock of $0.126 per share. The dividend is to be paid on Friday, June 01st, 2018, to holders of record on Friday, April 20th, 2018.
On February 16th, 2018, research firm Stifel reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $84 a share to $86 a share. See the free research coverage on ZTS at: www.wallstequities.com/registration/?symbol=ZTS
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: email@example.com Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/quotidian-technical-highlights-on-selected-generic-drugs-stocks----rigel-pharma-medicines-co-versartis-and-zoetis-300606514.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
Pneumonitis usually refers to inflammation of lung tissue due to various non-infective causes such ...
Fremanezumab-vfrm is used as a preventive treatment for a migraine headache in adult patients. It ...
DOOR syndrome is a rare genetic disorder marked by deafness, short or absent fingernails, abnormal ...View All